Centry Pharma, Inc. — Form D/A
Centry Pharma, Inc. of FORT LEE, NJ, a company, filed a Form D amendment with the SEC on 2021-10-29. The offering totals $15.3M, of which $15.3M was reported sold. Industry: Pharmaceuticals.
Offering
- Filed: 2021-10-29
- Form: D/A
- Accession: 0001104659-21-131756
- Industry: Pharmaceuticals
- Exemptions: 06b
- Total offering: $15.3M
- Amount sold: $15.3M
- Minimum investment: $20K
- Investors: 43
- Date of first sale: 2021-05-23
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-406723
Issuer
- Name: Centry Pharma, Inc.
- CIK: 0001859637
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2020
- Address: 1 BRIDGE PLAZA, FORT LEE, NJ, 07024
- Phone: (201) 614-3151
Officers, directors & promoters (8)
| Name | Role | Location |
|---|
| Ron Bentsur | Director | Fort Lee, NJ |
| Kenneth Hoberman | Director | New York, NY |
| Matthew Kaplan | Director | New York, NY |
| James Oliviero | Director | Fort Lee, NJ |
| Uri Ben-Or | Executive Officer | Fort Lee, NJ |
| Ron Bentsur | Executive Officer | Fort Lee, NJ |
| Enrique Poradosu | Executive Officer | Fort Lee, NJ |
| Shay Shemesh | Executive Officer | Fort Lee, NJ |
Other filings by this issuer (1)
More